Lyell Immunopharma, Inc
Price
FilingsNewest: 8-K, Other eventsSep 10 →Insiders14 insiders bought $25.0M in 2 open-market buys. 6 insiders sold $604,586, 2 of 28 sales on a 10b5-1 plan.→HoldersARCH Venture 13.9%GSK 6.5%Vanguard 3.4%→Financing →PeersClosest companies: FATE, CABA, IPSC→
From the filings
Figures
- Revenue
- $27,000last 12 months
- Net income
- −$248.5Mlast 12 months
- Operating cash flow
- −$133.8Mlast 12 months
- Cash and equivalents
- $73.0Mat the last balance sheet
- Shares outstanding
- 23.4M shareson issue